CDX
SU-DHL-2
Tumor indication
Lymphoma
Description
SU-DHL-2 (Lymphoma CDX Model)
The SU-DHL-2 line was derived from a patient with diffuse large B-cell lymphoma (DLBCL). It represents aggressive B-cell malignancies. SU-DHL-2 has been extensively used in lymphoma drug discovery. Its consistent biology makes it a reliable translational research model.
Key Features:
- Derived from diffuse large B-cell lymphoma.
- Aggressive B-cell lymphoma phenotype.
- Suspension culture morphology.
- Tumorigenic in xenografts.
Applications:
SU-DHL-2 supports development of novel therapies for DLBCL. It is applied in biomarker validation and signaling pathway studies. Researchers employ it in drug resistance and therapeutic testing. Its reproducibility makes it valuable for translational hematology pipelines.
Details
- Tumor indication
- Lymphoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.